Statistical and practical considerations in planning and conduct of dose-optimization trials

被引:7
作者
Yuan, Ying [1 ,3 ]
Zhou, Heng [2 ]
Liu, Suyu [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr Houston, Dept Biostat, Houston, TX USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA
[3] Univ Texas MD Anderson Canc Ctr Houston, Dept Biostat, Houston, TX 77030 USA
关键词
Optimal dose; benefit-risk trade-off; Project Optimus; adaptive design; CONTINUAL REASSESSMENT METHOD; II CLINICAL-TRIALS; ADAPTIVE RANDOMIZATION; TARGETED THERAPIES; ORDINAL TOXICITY; INTERVAL DESIGN; FINDING DESIGN; PHASE; EFFICACY; SELECTION;
D O I
10.1177/17407745231207085
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The U.S. Food and Drug Administration launched Project Optimus with the aim of shifting the paradigm of dose-finding and selection toward identifying the optimal biological dose that offers the best balance between benefit and risk, rather than the maximum tolerated dose. However, achieving dose optimization is a challenging task that involves a variety of factors and is considerably more complicated than identifying the maximum tolerated dose, both in terms of design and implementation. This article provides a comprehensive review of various design strategies for dose-optimization trials, including phase 1/2 and 2/3 designs, and highlights their respective advantages and disadvantages. In addition, practical considerations for selecting an appropriate design and planning and executing the trial are discussed. The article also presents freely available software tools that can be utilized for designing and implementing dose-optimization trials. The approaches and their implementation are illustrated through real-world examples.
引用
收藏
页码:273 / 286
页数:14
相关论文
共 75 条
[21]   Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials [J].
Li, Daniel H. ;
Whitmore, James B. ;
Guo, Wentian ;
Ji, Yuan .
CLINICAL CANCER RESEARCH, 2017, 23 (01) :13-20
[22]  
Lin R., 2020, JCO PRECIS ONCOL, V16, P1392
[23]   Bayesian optimal interval design with multiple toxicity constraints [J].
Lin, Ruitao .
BIOMETRICS, 2018, 74 (04) :1320-1330
[24]   STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials [J].
Lin, Ruitao ;
Yin, Guosheng .
STATISTICS IN MEDICINE, 2017, 36 (26) :4106-4120
[25]   A Bayesian Phase I/II Trial Design for Immunotherapy [J].
Liu, Suyu ;
Guo, Beibei ;
Yuan, Ying .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2018, 113 (523) :1016-1027
[26]   A robust Bayesian dose-finding design for phase I/II clinical trials [J].
Liu, Suyu ;
Johnson, Valen E. .
BIOSTATISTICS, 2016, 17 (02) :249-263
[27]   Bayesian optimal interval designs for phase I clinical trials [J].
Liu, Suyu ;
Yuan, Ying .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2015, 64 (03) :507-523
[28]   Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study [J].
Lonial, Sagar ;
Lee, Hans C. ;
Badros, Ashraf ;
Trudel, Suzanne ;
Nooka, Ajay K. ;
Chari, Ajai ;
Abdallah, Al-Ola ;
Callander, Natalie ;
Lendvai, Nikoletta ;
Sborov, Douglas ;
Suvannasankha, Attaya ;
Weisel, Katja ;
Karlin, Lionel ;
Libby, Edward ;
Arnulf, Bertrand ;
Facon, Thierry ;
Hulin, Cyrille ;
Kortum, K. Martin ;
Rodriguez-Otero, Paula ;
Usmani, Saad Z. ;
Hari, Parameswaran ;
Baz, Rachid ;
Hang Quach ;
Moreau, Philippe ;
Voorhees, Peter M. ;
Gupta, Ira ;
Hoos, Axel ;
Zhi, Eric ;
Baron, January ;
Piontek, Trisha ;
Lewis, Eric ;
Jewell, Roxanne C. ;
Dettman, Elisha J. ;
Popat, Rakesh ;
Esposti, Simona Degli ;
Opalinska, Joanna ;
Richardson, Paul ;
Cohen, Adam D. .
LANCET ONCOLOGY, 2020, 21 (02) :207-221
[29]   An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations [J].
Mandrekar, Sumithra J. ;
Cui, Yue ;
Sargent, Daniel J. .
STATISTICS IN MEDICINE, 2007, 26 (11) :2317-2330
[30]   A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy [J].
Msaouel, Pavlos ;
Goswami, Sangeeta ;
Thall, Peter F. ;
Wang, Xuemei ;
Yuan, Ying ;
Jonasch, Eric ;
Gao, Jianjun ;
Campbell, Matthew T. ;
Shah, Amishi Yogesh ;
Corn, Paul Gettys ;
Tam, Alda L. ;
Ahrar, Kamran ;
Rao, Priya ;
Sircar, Kanishka ;
Cohen, Lorenzo ;
Basu, Sreyashi ;
Duan, Fei ;
Jindal, Sonali ;
Zhang, Yuwei ;
Chen, Hong ;
Yadav, Shalini S. ;
Shazer, Ronald ;
Der-Torossian, Hirak ;
Allison, James P. ;
Sharma, Padmanee ;
Tannir, Nizar M. .
SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (641)